###### Key messages

What is already known about this subject?
=========================================

-   With the possibility to taper medication, disease-modifying antirheumatic drugs (DMARD)-free remission (DFR) is suggested as a preferred ultimate goal. However, data on the ability of reaching DFR in patients with established rheumatoid arthritis (RA) are currently lacking. Also data on the best tapering strategy are limited.

What does this study add?
=========================

-   The order of tapering did not affect flare rates, disease activity or physical functioning.

-   DFR is achievable in 15% of patients with established RA, and therefore reachable in a minority of patients. DFR was seen slightly more frequent in patients that tapered their conventional synthetic DMARDs first.

How might this impact on clinical practice or future developments?
==================================================================

-   Because of similar effects from a clinical viewpoint, financial arguments may influence the decision to taper tumour necrosis factor inhibitors first.

Introduction {#s1}
============

In rheumatoid arthritis (RA) disease, outcomes have improved tremendously in the last decades, mainly due to early initiation of therapy, a treat-to-target approach and intensive therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologicals. As a result, remission in RA occurs more frequently.[@R1]

If patients are successfully treated and the disease is well controlled, the patient as well as the treating physician will explore the possibility to taper medication. Reasons for tapering medication are among others reduction in costs, patient preference and prevention of (long-term) side effects. Tapering treatment may, however, lead to more transient or persistent disease flares with potential harmful consequences.[@R2] Previous research already showed that it is possible to taper DMARDs in RA and, therefore, current treatment recommendations advise to consider tapering therapy when patients with RA are in sustained remission.[@R2] However, there is no consensus on the best tapering strategy.

With the possibility to taper, the final step in tapering is to fully stop DMARDs. It has been suggested that sustained DMARD-free remission (DFR, which is defined as the absence of synovitis after cessation of DMARD therapy) is a preferred ultimate outcome of RA. Previous research in early RA populations showed that 10%--20% of patients with RA are able to achieve this outcome,[@R6] which was independent of the chosen treatment strategy.[@R7] However, it is currently unknown if reaching DFR is a reachable outcome in established RA.

Therefore, the aim of this study is to evaluate the 2-year clinical effectiveness of two gradual tapering strategies, namely tapering the csDMARD first followed by the tumour necrosis factor inhibitor (TNF-inhibitor), or vice versa, in patients with established RA. We will also explore the possibility to reach DFR within this population.

Patients and methods {#s2}
====================

Patient population {#s2-1}
------------------

Patients studied were included in the TApering strategies in Rheumatoid Arthritis (TARA) trial (NTR2754). Inclusion started September 2011 and ended July 2016. The TARA trial was a multicentre, single-blinded randomised trial, and was carried out in 12 rheumatology centres in the south-western part of the Netherlands.[@R8] Adult patients with RA with well-controlled disease, defined as a Disease Activity Score (DAS) ≤2.4 and a swollen joint count (SJC) ≤1 at two consecutive time points within a 3-month interval, using a combination of a csDMARD and TNF-inhibitor, were included. Medical ethics committees of each participating centre approved the protocol and all patients gave written informed consent before inclusion.

Randomisation and blinding {#s2-2}
--------------------------

Patients were randomised using minimisation randomisation stratified for centre. Trained research nurses, blinded to the allocated tapering arm, examined patients and calculated the DAS.

Tapering schedule {#s2-3}
-----------------

Patients were randomised into tapering the csDMARD in the first year followed by tapering the TNF-inhibitor in the second year, or vice versa. The csDMARD as well as the TNF-inhibitor were gradually tapered to discontinuation in three steps. Tapering csDMARDs was realised by cutting the dosage into half, a quarter and thereafter it was stopped. TNF-inhibitors were tapered by doubling the dose interval, followed by cutting the dosage into half, and thereafter it was stopped. The total tapering schedule for each drug took 6 months, with dose adjustments every 3 months as long as there was still a well-controlled disease. At the start of the study, patients were asked to refrain from glucocorticoids (GCs). There were no restrictions on the use of non-steroidal anti-inflammatory drugs or intra-articular GC injections.

The protocol was terminated in case of a flare (DAS \>2.4 and/or SJC\>1). The previous effective dose was restarted and if necessary, medication was intensified further according to a treat-to-target approach, until low disease activity was reached again. After a flare, no further attempts were taken to taper medication during the remainder of the study.

Assessments and outcomes {#s2-4}
------------------------

Patients were examined at baseline and every 3 months thereafter. At each time point, the DAS, medication usage and self-reported questionnaires were collected, except for hand and foot radiographs, which were obtained at baseline and after 1 and 2 years of follow-up. Throughout the whole study, follow-up (serious) adverse events (AEs) were recorded.

The primary outcome was the proportion of patients with a disease flare within the entire follow-up period of 2 years. Secondary endpoints were (1) the proportion of patients going through the entire tapering protocol, (2) DFR, (3) disease activity, (4) functional ability, (5) radiographic progression and (6) AEs.

Disease activity was measured with the DAS. Functional ability was measured with the Health Assessment Questionnaire Disability Index (HAQ-DI).[@R9] Higher HAQ-DI scores indicate poorer function. Radiographic progression was measured with the modified total Sharp score (mTSS).[@R10] Radiographs were scored chronologically by two out of three qualified assessors, who were blinded for study allocation and the identity of the patients.[@R11] Median mTSS is reported.[@R12] The weighted overall κ was 0.75 with \>99% agreement. The percentage of patients with radiographic progression, defined as a change in mTSS \>0.5 and\>1.3 (the smallest detectable change over 2 years) is given.[@R12] Safety monitoring took place according to Dutch guidelines, and included laboratory tests every 3 months.[@R13] The medication was stopped or the dosage was lowered in case of AEs related to medication use.

Statistical analysis {#s2-5}
--------------------

The TARA trial was a superiority trial, powered to detect a 20% difference in flare rates between both tapering strategies after 1 year of follow-up, using a significance level of α=0.05 and a power of 80%, which was previously described elsewhere.[@R16] For the current analysis, outcomes were calculated in an intention-to-treat analysis. Differences between groups in (1) cumulative flare rates, (2) proportion of patients going through the entire tapering protocol and (3) proportion of patients who reached DFR were analysed using logistic regression models. Missing data were imputed for these three analyses making use of using the last observation carried forward method. Flare-free survival was visualised with Kaplan-Meier curves, in which patients who were lost to follow-up were censored. Linear mixed models with maximum likelihood optimisation were used to compare DAS and HAQ-DI over time. Statistical comparisons of outcomes were made by Student's t-test, χ^2^ test or Wilcoxon rank-sum test when appropriate. All data were analysed using STATA V.15. A p value≤0.05 was considered statistically significant.

Patient and public involvement {#s2-6}
------------------------------

Patient partners are regularly consulted as advisor for all ongoing projects in the Erasmus MC. The patient panel of the Erasmus MC consist of 15--20 patients of different age, sex and with different rheumatic diseases. Study results and study proposals are discussed on a regular basis. For the TARA study, patients were consulted for the design of the study, developing the research question and outcome parameters.

Results {#s3}
=======

Patients {#s3-1}
--------

A total of 189 patients were randomly assigned to taper their csDMARD (n=94) or TNF-inhibitor (n=95) first ([figure 1](#F1){ref-type="fig"}). After 2 years of follow-up, 13 and 9 patients dropped out of the study, and complete follow-up data were obtained for 167 patients ([figure 1](#F1){ref-type="fig"}). Patients had a median symptom duration of 6.2 years and were predominantly female (66%) with an average age of 56.6 years ([table 1](#T1){ref-type="table"}). Within the group who tapered the csDMARD first, 80% had DAS remission (DAS44 \<1.6), compared with 88% of patients who tapered their TNF-inhibitor first. Furthermore, 33% of patients in the group who tapered the csDMARD first and 37% of the group who tapered the TNF-inhibitor first were in Boolean remission, defined as tender joint count (TJC) 28 ≤1, SJC28 ≤1, C reactive protein (CRP) ≤10 mg/L and patient global assessment (PGA)≤10 mm (0--100 mm scale) at baseline ([table 1](#T1){ref-type="table"}).

![Flow chart of the TApering strategies in Rheumatoid Arthritis trial. Trial profile and patient participation are indicated as numbers of patients. csDMARD, conventional synthetic disease-modifying antirheumatic drug; LTFU, lost to follow-up; TNF-inhibitor, tumour necrosis factor inhibitor.](annrheumdis-2020-217485f01){#F1}

###### 

Baseline characteristics of patients

  Characteristics                               Tapering csDMARD first (n=94)   Tapering TNF-inhibitor first (n=95)
  --------------------------------------------- ------------------------------- -------------------------------------
  Demographic                                                                   
   Age (years), mean (95% CI)                   55.9 (53.0 to 58.8)             57.2 (55.0 to 59.4)
   Gender, female, n (%)                        67 (71)                         58 (61)
  Disease characteristics                                                       
   Symptom duration (years), median (IQR)       6.0 (4.1--8.5)                  6.4 (4.2--8.9)
   RF positive, n (%)                           50 (57)                         59 (65)
   ACPA positive, n (%)                         62 (71)                         67 (75)
  Disease activity                                                              
   DAS44, mean (95% CI)                         1.1 (0.9 to 1.2)                1.0 (0.9 to 1.1)
   DAS clinical remission, DAS44 \<1.6, n (%)   75 (80)                         84 (88)
   Boolean remission, n (%)                     31 (33)                         35 (37)
   HAQ-DI, mean (95% CI)                        0.52 (0.42 to 0.62)             0.47 (0.35 to 0.58)
  Use of csDMARDs\*                                                             
   MTX monotherapy, n (%)                       64 (69)                         49 (52)
   MTX +HCQ, n (%)                              18 (19)                         27 (29)
   MTX +SASP + HCQ, n (%)                       5 (5)                           6 (6)
   MTX +SASP, n (%)                             3 (3)                           2 (2)
   MTX +LEF, n (%)                              1 (1)                           0 (0)
   SASP monotherapy, n (%)                      0 (0)                           3 (3)
   SASP +HCQ, n (%)                             2 (2)                           0 (0)
   SASP +LEF, n (%)                             0 (0)                           1 (1)
   LEF monotherapy, n (%)                       1 (1)                           3 (3)
   LEF +HCQ, n (%)                              0 (0)                           1 (1)
   HCQ monotherapy, n (%)                       0 (0)                           3 (3)
  Use of TNF-inhibitor                                                          
   Etanercept, n (%)                            51 (54)                         52 (55)
   Adalimumab, n (%)                            37 (39)                         40 (42)
   Certolizumab, n (%)                          2 (2)                           2 (2)
   Golimumab, n (%)                             4 (4)                           1 (1)
  Use of glucocorticosteroids, n (%)                                            
   Oral, n (%)                                  1 (1)                           0 (0)
  Radiographs (hand/foot)                                                       
   mTSS (0--488), median (IQR)                  2 (0--6.5)                      1 (0--3.5)
   Erosive disease, n (%) †                     37 (39)                         26 (27)

\*Some patients used a combination of conventional synthetic disease-modifying antirheumatic drug (csDMARDs).

†Erosive disease is characterised as having \>1 erosion in three separate joints.

ACPA, anticitrullinated protein antibody; DAS44, Disease Activity Score measured in 44 joints; HAQ-DI, Health Assessment Questionnaire Disability Index; HCQ, hydroxychloroquine; LEF, leflunomide; mTSS, modified Sharp/Van der Heijde score; MTX, methotrexate; RF, rheumatoid factor; SASP, sulfasalazine; TNF, tumour necrosis factor.

Primary outcome {#s3-2}
---------------

After 2 years of follow-up, flare rates (95% CI) were 61% (50% to 71%) in the group who tapered the csDMARD first, and 62% (52% to 72%) in the group who tapered the TNF-inhibitor first (p=0.84; [figure 2](#F2){ref-type="fig"}). The median time-to-flare (IQR) was 9.5 (6.5--21) months for patients tapering the csDMARD first, and 12 (6.5--15.5) months for patients tapering the TNF-inhibitor first. Median flare duration (IQR) was for both tapering groups 3 (3--6) months. Use of GCs was similar for both tapering arms ([online supplementary table S1](#SP1){ref-type="supplementary-material"}).
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![Disease activity over time. (A) Kaplan-Meier of flare-free survival, numbers below the graph indicate the number of patients at risk, (B) mean Disease Activity Score (DAS) based on 44 joints over time, (C) percentage of patients in DAS remission (DAS44 \<1.6) indicated with solid lines and the percentage of patients in Boolean remission: TJC28 ≤1, SJC28 ≤1, C reactive protein ≤10 mg/L, PGA≤10 mm (0--100 mm scale) indicated with dotted lines, (D) functional ability measured with HAQ over time. Error bars indicate 95% CIs. Numbers below graphs indicate mean values of the outcome per tapering arm, per time point, unless other indicated. csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; TNF-inhibitor, tumour necrosis factor inhibitor.](annrheumdis-2020-217485f02){#F2}

DMARD-free remission {#s3-3}
--------------------

Of the patients who tapered, respectively, their csDMARD and TNF-inhibitor first, 29 (31%) and 20 (21%) were able to go through the entire tapering protocol of tapering their TNF-inhibitor and 1 csDMARD (p=0.12) ([figure 3](#F3){ref-type="fig"}). None of these patients experienced a flare after withdrawal of the csDMARD and TNF-inhibitor (period between 18 and 24 months of follow-up). Although these patients went through the entire tapering protocol, not all of them were in DFR, because some were using a combination of csDMARDs at baseline ([table 1](#T1){ref-type="table"}) and in the protocol only one csDMARD was tapered. This means that from the total amount of patients who tapered according to protocol, not all were in DFR. In total, 19 (20%) patients tapering csDMARDs first and 10 (11%) patients tapering TNF-inhibitor first were in DFR after 24 months of follow-up (p=0.07). In both groups, all patients reached DFR after 18 months of follow-up, and none of them used glucocorticosteroids in the period thereafter.

![Overview of medication use throughout 2 years of follow-up. In the first year, data were used of all patients; for the second year, only data were shown for patients who actually tapered their medication. When patients had a flare, it was no longer allowed to continue tapering throughout the rest of the study. (A) Disease-modifying antirheumatic drugs (DMARD) usage over time indicated for the two tapering arms, given as percentages of patients. (B) DMARD usage after 24 months. Each bar represents a certain dosage of the conventional synthetic DMARD (csDMARD) and the tumour necrosis factor inhibitor (TNF-inhibitor), ranging from no tapering on top (full dose, FD) to discontinuation of the csDMARD and the TNF-inhibitor below. Numbers (%) next to bars indicate the number of patients who reached the indicated level of tapering after following the protocol for 24 months, as a percentage of the original TApering strategies in Rheumatoid Arthritis population.](annrheumdis-2020-217485f03){#F3}

Disease activity, functional ability and radiographic progression {#s3-4}
-----------------------------------------------------------------

No significant differences were found in disease activity (p=0.45) and functional ability (p=0.17) between both tapering groups over time ([figure 2](#F2){ref-type="fig"}). The percentage of patients in Boolean remission after 1 year of follow-up decreased from 33% to 20% in the group who tapered the csDMARD first and from 37% to 18% in the group who tapered the TNF-inhibitor first, and in the second year these percentages stabilised ([figure 2](#F2){ref-type="fig"}). Median (IQR) mTSS scores were 3 (0--7.5) in the csDMARD and 1 (0--4.5) in the TNF-inhibitor tapering group after 2 years of follow-up. The cumulative probability plots of both groups were similar ([figure 4](#F4){ref-type="fig"}). Radiographic progression, defined as an mTSS increase of \>1.3, occurred in 6.1% of the patients in the csDMARD-tapering group and 7.5% of the patients in the TNF-inhibitor tapering group (p=0.8). These percentage were, respectively, 16.3% and 20% if we use an mTSS increase of \>0.5 as definition for radiographic progression (p=0.9). An increase in erosive disease (\>1 erosion in 3 separate small hand or feet joints) after 2 years of follow-up was observed in 6.4% of patients who tapered the csDMARD first, and in 11.6% of patients who tapered their TNF-inhibitor first.

![Radiological progression within the 2 years of follow-up. Radiological progression was measured with the modified total Sharp score (mTSS). csDMARD, conventional synthetic disease-modifying antirheumatic drug; TNF-inhibitor, tumour necrosis factor inhibitor.](annrheumdis-2020-217485f04){#F4}

Adverse events {#s3-5}
--------------

In total, 15 (8%) serious AEs were reported. None of them were reported as being related to the study medication ([table 2](#T2){ref-type="table"}). At baseline, self-reported AEs were collected and 47.1% of all patients reported side effects. No differences were found between both tapering groups regarding the number of AEs reported and the burden of AEs ([table 2](#T2){ref-type="table"}). However, when assessing each drug separately, then AEs were more often reported for methotrexate compared with the TNF-inhibitor (35% vs 23%, p=0.02). The AEs related to MTX also had more impact on patients' life compared with AEs related to the TNF-inhibitor (20 vs 8.8, p\<0.0001, measured with a Visual Analogue Scale; [table 2](#T2){ref-type="table"}). The self-reported AEs and their impact on patients' lives were all measured before actual tapering commenced.

###### 

Adverse events (AEs)

  AEs                                                          Tapering csDMARD first (n=94)   Tapering TNF-inhibitor first (n=95)
  ------------------------------------------------------------ ------------------------------- -------------------------------------
  MTX                                                                                          
   Patients reporting AE due to MTX                            32 (34)                         35 (37)
   Off day                                                     7 (7)                           8 (8)
   Nausea                                                      22 (23)                         18 (19)
   Fatigue                                                     7 (7)                           8 (8)
   Acne                                                        0 (0)                           3 (3)
   Hair loss                                                   5 (5)                           5 (5)
   Abnormalities of oral mucosa                                1 (1)                           3 (3)
   Headache                                                    1 (1)                           0 (0)
  Burden of AE due to MTX, VAS (0--100), mean (SD)             20 (27)                         20 (27)
  TNF-inhibitor                                                                                
   Patients reporting AE due to TNF-inhibitor                  23 (24)                         21 (22)
   Pain of injection                                           13 (14)                         7 (7)
   Fear of injection                                           3 (3)                           4 (4)
   Irritation at place of injection                            8 (9)                           10 (11)
   General skin changes                                        5 (5)                           3 (3)
   Itch                                                        1 (1)                           1 (1)
   Gastrointestinal complaints                                 2 (2)                           2 (2)
   Fatigue                                                     2 (2)                           1 (1)
  Burden of AE due to TNF-inhibitor, VAS (0--100), mean (SD)   7.6 (12)                        10 (19)
  Serious AE\*                                                 10 (12)                         5 (6)

\*Serious AEs per tapering arm were, respectively: tapering conventional synthetic disease-modifying antirheumatic drug (csDMARDs) first 7 × hospitalisation (3 × total hip replacement surgery, 1 × pneumonia, 1 × decompression shoulder, 1 × pancreatitis, 1 × angina pectoris), 1 × herpes zoster, 1 × basal cell carcinoma, 1 × large-cell lung carcinoma; tapering tumour necrosis factor inhibitor (TNF-inhibitor) first 4 × hospitalisation (2 × peripheral vascular disease, 1 × total knee replacement, 1 × myocardial infarction), 1 × bruised rib.

MTX, methotrexate; VAS, Visual Analogue Scale.

Discussion {#s4}
==========

In this study, the 2-year clinical effectiveness of two gradual tapering strategies in established RA was evaluated. The first strategy consisted of tapering the csDMARD first followed by the TNF-inhibitor, the second strategy consisted of tapering the TNF-inhibitor first, followed by the csDMARD. After 2 years of follow-up, 61% and 62% of patients who, respectively, tapered their csDMARD or TNF-inhibitor first experienced a disease flare. Also, no differences were seen in disease activity, functional ability, radiographic progression and serious AEs. Furthermore, 31% and 21% of patients were able to complete the entire tapering protocol. After 2 years, 20% and 11% of patients were in DFR.

The flare rates within the TARA trial were high, but within the range of previous reported flare rates (51%--77%).[@R17] Also, our median flare duration, which was 3 months, is comparable with previous tapering studies.[@R3] This underlines the robustness of the current data and suggests that these flare rates are generalisable to clinical practice.

DFR is nowadays the closest to actual cure of RA, which might be reached by controlled tapering of medication in part of the patients. However, data on achieving DFR in patients with established RA are sparse. The Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission (RETRO) study showed that 13 out of 27 patients with established RA (48%) were able to reach DFR. However, these data were based on a very low sample size.[@R21] Our DFR rate is comparable with the Leiden Early Arthritis Cohort; 158/889 (17.8%), however, direct comparison is hampered due to various reasons, among which the difference in study design, disease stage (early vs established RA) and duration of being in DFR.[@R6] In particular, the duration of DFR is an important measure of sustainability, and inversely related to the frequency of disease flares.[@R22]

In both tapering groups, all patients who reached DFR, reached it after 18 months of follow-up. Interestingly, none of those patients experienced a flare in the 6 months after DMARD stop, whereas other studies reported flare rates between 5% and 25% in the first 6 months after achieving DFR.[@R23] Since clearance can take more than 6 months for certain TNF-inhibitors, we might have overestimated the proportion of patients in DFR, in the group who tapered their csDMARDs first. Nonetheless, differences between groups were not significant, and we found similar flare rates in both tapering groups, which indicates that our final results are valid. Still, optimal follow-up for assessing DFR should be longer than 6 months.

A limitation of the TARA trial is that we allowed the use of \>1 csDMARD. Because only one of the csDMARDs was tapered according to protocol, not all patients who went through the entire tapering protocol were in DFR. Ideally, we should have included only those patients who used one csDMARD combined with a TNF-inhibitor. However, subgroup analysis revealed that tapering was not more successful in patients who used multiple csDMARDs compared with the patients who used only one csDMARD.

One could argue that tapering should only take place when patients are in a 'deep' sustained remission to increase the chance at DFR and to minimise the risk of flare. Current European League Against Rheumatism (EULAR) guidelines advise to only taper medication in case of persistent remission, preferably Boolean based.[@R5] For the TARA trial, we used a DAS \<2.4 combined with maximum of one swollen joint, instead of the proposed remission criteria by the EULAR. This was chosen, because of a low inclusion rate. Furthermore, at time of recruitment, another trial was set up making use of the same eligibility criteria. Although we used less stringent criteria to start tapering therapy, our flare rates were comparable to other tapering strategies. Furthermore, within our study, no association was found between being in Boolean remission at baseline and staying flare-free during follow-up. This suggests that Boolean remission on its own is not a good predictor for flare-free survival when medication is tapered. Moreover, if persistent Boolean remission is the prerequisite for tapering therapy, fewer patients will be eligible for tapering, while in our trial only 33 (17%) patients were not able to taper any treatment.

Although 15% of our patients with established RA were able to reach DFR, it is arguable whether this outweighs the risk of a disease flare (61% in our study). Especially, since it was recently shown that disease flares have a significant effect on patients' lives, with a duration of more than 6 months.[@R27]

Ideally, rheumatologists want to be more certain about which patient is able to taper successfully, as current tapering strategies are based on a trial-and-error approach, which results in high flare rates that significantly influence patients' lives. Unfortunately, we still do not know which patients are more eligible for tapering and whom will have a higher chance at reaching DFR. Present data (re)confirmed that tapering treatment is possible and that DFR is achievable in a small proportion of patients even within those with an established RA. In our opinion, future studies should focus on patient subsets eligible to (continue) taper medication to reduce the amount of flares and to increase the number of patients that reach DFR.

In conclusion, the order of tapering did not affect flare rates, disease activity or physical functioning. In total, 61% of patients had a flare in the 2 years of follow-up. DFR was achievable in a small proportion of patients and was seen slightly more frequent in patients that tapered their csDMARDs first. Because of similar effects from a clinical perspective, financial arguments may influence the decision to taper TNF-inhibitors first.
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